Primary source: Cancellation of Notified Cosmetic Products
The NPRA has enforced the cancellation of cosmetic products that were found to contain harmful ingredients, including mercury and hydroquinone, which pose serious health risks.
This cancellation is critical for public safety, preventing consumers from exposure to harmful chemicals linked to severe health risks, including kidney damage and neurological issues.
Sellers must stop the sale and distribution of the canceled products immediately and monitor for compliance with NPRA regulations to avoid legal penalties.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Sellers must stop the sale and distribution of the canceled products immediately and monitor for compliance with NPRA regulations to avoid legal penalties.
Vendors must ensure that all products listed are removed from sale and distribution.
Strict enforcement of product cancellation and monitoring for compliance.
Increased reporting and investigation of complaints related to these products.
Enhanced vigilance required for monitoring adverse effects from products previously in circulation.
Sellers must stop the sale and distribution of the canceled products immediately and monitor for compliance with NPRA regulations to avoid legal penalties.
The National Pharmaceutical Regulatory Agency (NPRA) in Malaysia has announced the cancellation of several notified cosmetic products that contain prohibited substances such as mercury and hydroquinone. These cancellations require immediate action from sellers to cease the distribution and sale of these products.
What changed: The NPRA has enforced the cancellation of cosmetic products that were found to contain harmful ingredients, including mercury and hydroquinone, which pose serious health risks.
Why it matters: This cancellation is critical for public safety, preventing consumers from exposure to harmful chemicals linked to severe health risks, including kidney damage and neurological issues.
Practical implication: Sellers must stop the sale and distribution of the canceled products immediately and monitor for compliance with NPRA regulations to avoid legal penalties.
Published from the regulator source ingestion pipeline after PV impact triage.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
